Skip to main content
Johnson & JohnsonIn development

Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily...

Source: Autobound Signal API · 88 signals tracked for Johnson & Johnson · updated

Get Johnson & Johnson's live signals in Claude or ChatGPT, or by API

AskWhat changed at Johnson & Johnson this week? Use Autobound signals for jnj.com.

What happened

Johnson & Johnson announced positive Phase 3 results for its investigational targeted oral peptide ICOTYDE (icotrokinra) in treating biologic-naive adults with active psoriatic arthritis.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

NEW BRUNSWICK, N.J., Nov. 7, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced positive results from a Phase 3 study investigating ICOTYDE ® (icotrokinra) in biologic-naïve adults with active psoriatic arthritis (PsA). a,b ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor. 1 ICOTYDE met the primary endpoint, with 58% of patients achieving an American College of Rheumatology 20 (ACR20) response compared with 41% receiving placebo at Week 16. 2 Safety findings were consistent with the established safety profile of ICOTYDE, with no new safety signals identified. These results are being presented as a late-breaking poster at the American College of Rheumatology (ACR) Convergence 2026. Psoriatic arthritis is a chronic, immune-mediated inflammatory disease that can affect both the joints and skin. 3,4 Nearly 30 percent of people with plaque psoriasis also develop psoriatic arthritis. 5,6 It can cause pain, stiffness and swelling in and around the joints, along with the skin lesions associated with plaque psoriasis. 7 Because inflammation can lead to progressive disease, there remains a need for treatment approaches that address the multiple ways psoriatic arthritis can affect patients. In clinical studies, ACR response is a composite measure whereby ACR20 represents ≥20% improvement in tender joint count, swollen joint...

Keep reading with a free account

The rest of this article, and every signal for Johnson & Johnson, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
ICOTYDE
Takes effect
Nov 7, 2026
Location
New Brunswick, New Jersey, United States

The full record

From the Signal API record

Details

Ticker
NYSE:JNJ

Topics and mentions

Product tags

  • medical
  • general technology

Extraction

Confidence
95%
Detected
Nov 7, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Johnson & Johnson and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Johnson & Johnson this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/b7918f7e-5808-539c-b93e-a88a2b980229 returns this record as JSON. POST /v1/companies/enrich returns every signal for jnj.com.

{
  "signal_id": "b7918f7e-5808-539c-b93e-a88a2b980229",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-11-07T15:03:00+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/johnson--johnson-announces-icotyde-icotrokinra-delivers-significant-improvement-in-psoriatic-arthritis-disease-activity-among-biologic-naive-patients-with-once-daily-targeted-oral-peptide-302932455.html",
    "title": "Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide",
    "ticker": "NYSE:JNJ",
    "excerpt": "NEW BRUNSWICK, N.J. , Nov. 7, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced positive results from a Phase 3 study investigating ICOTYDE ® (icotrokinra) in biologic-naïve adults with active psoriatic arthritis (PsA). a,b ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor. 1 ICOTYDE met the primary endpoint, with 58% of patients achieving an American College of Rheumatology 20 (ACR20) response compared with 41% receiving placebo at Week 16. 2 Safety findings were consistent with the established safety profile of ICOTYDE, with no new safety signals identified. These results are being presented as a late-breaking poster at the American College of Rheumatology (ACR) Convergence 2026. Psoriatic arthritis is a chronic, immune-mediated inflammatory disease that can affect both the joints and skin. 3,4 Nearly 30 percent of people with plaque psoriasis also develop psoriatic arthritis. 5,6 It can cause pain, stiffness and swelling in and around the joints, along with the skin lesions associated with plaque psoriasis. 7 Because inflammation can lead to progressive disease, there remains a need for treatment approaches that address the multiple ways psoriatic arthritis can affect patients. In clinical studies, ACR response is a composite measure whereby ACR20 represents ≥20% improvement in tender joint count, swollen joint...",
    "product": "ICOTYDE",
    "summary": "Johnson & Johnson announced positive Phase 3 results for its investigational targeted oral peptide ICOTYDE (icotrokinra) in treating biologic-naive adults with active psoriatic arthritis.",
    "location": "New Brunswick, New Jersey, United States",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS225644/Johnson-and-Johnson-Logo-v1.jpg?id=OA3063807&p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "ICOTYDE",
      "full_text": "ICOTYDE ® (icotrokinra)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-11-07T15:03:00Z",
    "location_data": [
      {
        "city": "New Brunswick",
        "state": "New Jersey",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-11-07",
    "article_sentence": "Johnson & Johnson (NYSE: JNJ ) today announced positive results from a Phase 3 study investigating ICOTYDE ® (icotrokinra) in biologic-naïve adults with active psoriatic arthritis (PsA)."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.